Table 2 The somatic mutation spectrum in different renal carcinoma
From: Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases
Present study (n = 28) | Renal Clear Cell Carcinoma (n = 499) | Wilms Tumor (n = 102) | Papillary Renal Cell Carcinoma (n = 293) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene | Mutant | Freq | Gene | Mutant | Freq | Gene | Mutant | Freq | Gene | Mutant | Freq | |
1 | BRAF | 23 | 82% | VHL | 235 | 51% | TP53 | 15 | 15% | MET | 23 | 7% |
2 | NF1 | 6 | 21% | PBRM1 | 158 | 36% | HLA-DQB1 | 11 | 7% | KMT2C | 20 | 6% |
3 | NOTCH1 | 5 | 18% | MUC4 | 142 | 21% | CTNNB1 | 8 | 7% | MUC4 | 20 | 5% |
4 | SPEN | 5 | 18% | SETD2 | 60 | 13% | CDK11A | 6 | 6% | SETD2 | 19 | 6% |
5 | AKT2 | 4 | 14% | BAP1 | 44 | 10% | DROSHA | 7 | 6% | KIAA1109 | 17 | 6% |
6 | APC | 4 | 14% | KDM5C | 30 | 7% | TMPRSS13 | 5 | 4% | BAP1 | 16 | 5% |
7 | ATRX | 3 | 11% | MTOR | 23 | 5% | ADCK5 | 4 | 4% | AR | 16 | 5% |
8 | ETV4 | 3 | 11% | PABPC1 | 20 | 5% | WT1 | 4 | 4% | KMT2D | 15 | 5% |
9 | FANCD2 | 2 | 7% | AHNAK2 | 19 | 4% | SIX1 | 4 | 4% | PCLO | 14 | 4% |
10 | FAT3 | 2 | 7% | PTEN | 19 | 4% | MAP3K4 | 4 | 4% | FAT1 | 13 | 4% |
11 | KDM6A | 2 | 7% | ATM | 18 | 3% | ACTB | 3 | 3% | NEFH | 13 | 4% |
12 | KDR | 2 | 7% | KMT2C | 17 | 4% | ZNF880 | 3 | 3% | WDFY3 | 13 | 4% |
13 | NOTCH3 | 2 | 7% | MAGEC1 | 16 | 4% | ZNF595 | 3 | 3% | SYNE1 | 13 | 4% |
14 | TET2 | 2 | 7% | MUC6 | 16 | 3% | DGCR8 | 3 | 3% | CUL3 | 13 | 4% |
15 | TSC2 | 2 | 7% | LRP1B | 15 | 4% | AGRN | 3 | 3% | ZNF814 | 13 | 3% |
16 | PCLO | 15 | 4% | MADCAM1 | 4 | 3% | ALMS1 | 13 | 3% | |||
17 | SYNE1 | 15 | 4% | HYDIN | 3 | 3% | DNAH8 | 12 | 4% | |||
18 | ARID1A | 14 | 3% | CUBN | 12 | 4% | ||||||
19 | KMT2D | 14 | 3% | PBRM1 | 12 | 4% | ||||||
20 | MUC2 | 14 | 3% | PCF11 | 12 | 4% | ||||||